OncoMatch/Clinical Trials/NCT06071013
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Is NCT06071013 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Nintedanib, gefitinib, erlotinib, afatinib, osimertinib for non-small cell lung cancer.
Treatment: Nintedanib, gefitinib, erlotinib, afatinib, osimertinib — The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR mutation
Positive EGFR mutations are diagenesis
Required: PRKCD wild-type (nPKCδ expression not negative by IHC)
Participants have a known diagnosis of negative nPKCδ expression by immunohistochemistry (IHC) [excluded]
Disease stage
Required: Stage III, IV
Demographics
Prior therapy
Must have received: egfr tyrosine kinase inhibitor (gefitinib, erlotinib, afatinib, osimertinib) — first-line
Cannot have received: egfr tyrosine kinase inhibitor
Exception: serious side effects
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06071013 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior egfr tyrosine kinase inhibitor disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR mutation is a required biomarker for enrollment.
Does this trial require PRKCD?
Yes, PRKCD wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 20 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages